IBDEI0KE ; ; 18-NOV-2013
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;NOV 18, 2013
 Q:'DIFQR(358.4)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.4,1507,0)
 ;;=CYST^8.07^161
 ;;^UTILITY(U,$J,358.4,1508,0)
 ;;=DRUG REACTION^10.02^161
 ;;^UTILITY(U,$J,358.4,1509,0)
 ;;=LENTIGO^45^161
 ;;^UTILITY(U,$J,358.4,1510,0)
 ;;="O" DIAGNOSES^60^161
 ;;^UTILITY(U,$J,358.4,1511,0)
 ;;=PSYCHO CUTEANOUS DERMATITIS^64.5^161
 ;;^UTILITY(U,$J,358.4,1512,0)
 ;;="R" DIAGNOSES^65.5^161
 ;;^UTILITY(U,$J,358.4,1513,0)
 ;;="T" DIAGNOSES^67.5^161
 ;;^UTILITY(U,$J,358.4,1514,0)
 ;;=SCREENING^65.6^161
 ;;^UTILITY(U,$J,358.4,1515,0)
 ;;=NEOPLASM-MALIGNANT^55^161
 ;;^UTILITY(U,$J,358.4,1516,0)
 ;;="A" MISC DIAGNOSIS^1^162
 ;;^UTILITY(U,$J,358.4,1517,0)
 ;;="B" MISC DIAGNOSIS^2^162
 ;;^UTILITY(U,$J,358.4,1518,0)
 ;;="C" MISC DIAGNOSIS^3^162
 ;;^UTILITY(U,$J,358.4,1519,0)
 ;;="D" MISC DIAGNOSIS^5^162
 ;;^UTILITY(U,$J,358.4,1520,0)
 ;;="E/F" MISC DIAGNOSIS^6^162
 ;;^UTILITY(U,$J,358.4,1521,0)
 ;;="H" MISC DIAGNOSIS^8^162
 ;;^UTILITY(U,$J,358.4,1522,0)
 ;;="I" MISC DIAGNOSIS^9^162
 ;;^UTILITY(U,$J,358.4,1523,0)
 ;;="J/K/L" MISC DIAGNOSIS^10^162
 ;;^UTILITY(U,$J,358.4,1524,0)
 ;;="M" MISC DIAGNOSIS^11^162
 ;;^UTILITY(U,$J,358.4,1525,0)
 ;;="N/O" MISC DISGNOSIS^12^162
 ;;^UTILITY(U,$J,358.4,1526,0)
 ;;="P" MISC DIAGNOSIS^13^162
 ;;^UTILITY(U,$J,358.4,1527,0)
 ;;="V/W/X/Y/Z" MISC DIAGNOSIS^17^162
 ;;^UTILITY(U,$J,358.4,1528,0)
 ;;="S" MISC DIAGNOSIS^15^162
 ;;^UTILITY(U,$J,358.4,1529,0)
 ;;=CANCER (NOT MELANOMA)^4^162
 ;;^UTILITY(U,$J,358.4,1530,0)
 ;;="G" MISC DIAGNOSIS^7^162
 ;;^UTILITY(U,$J,358.4,1531,0)
 ;;="R" DIAGNOSES^14^162
 ;;^UTILITY(U,$J,358.4,1532,0)
 ;;="T/U" MISC DIAGNOSIS^16^162
 ;;^UTILITY(U,$J,358.4,1533,0)
 ;;=TELEHEALTH FACILITY FEE^1^163
 ;;^UTILITY(U,$J,358.4,1534,0)
 ;;=TELERETINAL PROCEDURES^1^164
 ;;^UTILITY(U,$J,358.4,1535,0)
 ;;=ORBIT/EYELID/LACRIMAL^8^165
 ;;^UTILITY(U,$J,358.4,1536,0)
 ;;=ANTERIOR SEGMENT/LACRIMAL^2^165
 ;;^UTILITY(U,$J,358.4,1537,0)
 ;;=LENS/CATARACT^5^165
 ;;^UTILITY(U,$J,358.4,1538,0)
 ;;=RETINA/VITREOUS/CHOROID^9^165
 ;;^UTILITY(U,$J,358.4,1539,0)
 ;;=NEUROLOGIC EYE DISEASE^7^165
 ;;^UTILITY(U,$J,358.4,1540,0)
 ;;=MEDICAL/SYSTEMIC/TRAUMA/OTHER^6^165
 ;;^UTILITY(U,$J,358.4,1541,0)
 ;;=GLAUCOMA^3^165
 ;;^UTILITY(U,$J,358.4,1542,0)
 ;;=STRABISMUS^10^165
 ;;^UTILITY(U,$J,358.4,1543,0)
 ;;=INFECTIONS/INFLAMMATION/CONJUNCTIVA^4^165
 ;;^UTILITY(U,$J,358.4,1544,0)
 ;;=MOST COMMON^1^165
 ;;^UTILITY(U,$J,358.4,1545,0)
 ;;=CARDIOVASCULAR^2^166
 ;;^UTILITY(U,$J,358.4,1546,0)
 ;;=RESPIRATORY^7^166
 ;;^UTILITY(U,$J,358.4,1547,0)
 ;;=SIGNS, SYMPTOMS, CONDITIONS^8^166
 ;;^UTILITY(U,$J,358.4,1548,0)
 ;;=COMMON DIAGNOSES^1^166
 ;;^UTILITY(U,$J,358.4,1549,0)
 ;;=POST-OP COMPLICATIONS^6^166
 ;;^UTILITY(U,$J,358.4,1550,0)
 ;;=AFTERCARE POST SURGERY^4^166
 ;;^UTILITY(U,$J,358.4,1551,0)
 ;;=METASTATIC CANCER SITES^5^166
 ;;^UTILITY(U,$J,358.4,1552,0)
 ;;=ABDOMINAL PAIN^3^166
 ;;^UTILITY(U,$J,358.4,1553,0)
 ;;=CHEST WALL AND NECK^1^167
 ;;^UTILITY(U,$J,358.4,1554,0)
 ;;=THORACIC^2^167
 ;;^UTILITY(U,$J,358.4,1555,0)
 ;;=OTHER PROCEDURES^3^167
 ;;^UTILITY(U,$J,358.4,1556,0)
 ;;=NEW PATIENT^2^168
 ;;^UTILITY(U,$J,358.4,1557,0)
 ;;=ESTABLISHED PATIENT^1^168
 ;;^UTILITY(U,$J,358.4,1558,0)
 ;;=CONSULTATIONS^3^168
 ;;^UTILITY(U,$J,358.4,1559,0)
 ;;=POST-OP FOLLOW-UP^4^168
 ;;^UTILITY(U,$J,358.4,1560,0)
 ;;=MALE URETHRAL DILATION^3^169
 ;;^UTILITY(U,$J,358.4,1561,0)
 ;;=MISCELLANEOUS^4^169
 ;;^UTILITY(U,$J,358.4,1562,0)
 ;;=URODYNAMICS^5^169
 ;;^UTILITY(U,$J,358.4,1563,0)
 ;;=ZOLADEX^6^169
 ;;^UTILITY(U,$J,358.4,1564,0)
 ;;=CYSTOURETHROSCOPY^1^169
 ;;^UTILITY(U,$J,358.4,1565,0)
 ;;=FEMALE ONLY PROCEDURES^2^169
 ;;^UTILITY(U,$J,358.4,1566,0)
 ;;=UNLISTED UROLOGY PROCEDURES^7^169
 ;;^UTILITY(U,$J,358.4,1567,0)
 ;;=NEW PATIENT^2^170
 ;;^UTILITY(U,$J,358.4,1568,0)
 ;;=ESTABLISHED PATIENT^1^170
 ;;^UTILITY(U,$J,358.4,1569,0)
 ;;=CONSULTATIONS^3^170
 ;;^UTILITY(U,$J,358.4,1570,0)
 ;;=POST OP VISIT (GLOBAL)^4^170
 ;;^UTILITY(U,$J,358.4,1571,0)
 ;;=OTHER E&M SERVICES^5^170
 ;;^UTILITY(U,$J,358.4,1572,0)
 ;;=NEURO-UROLOGY^15^171
 ;;^UTILITY(U,$J,358.4,1573,0)
 ;;=BLADDER^1^171
 ;;^UTILITY(U,$J,358.4,1574,0)
 ;;=KIDNEY/URETER^8^171
 ;;^UTILITY(U,$J,358.4,1575,0)
 ;;=PENIS/EXTERNAL GENITALIA^16^171
 ;;^UTILITY(U,$J,358.4,1576,0)
 ;;=PROSTATE^18^171
 ;;^UTILITY(U,$J,358.4,1577,0)
 ;;=POST OP^17^171
 ;;^UTILITY(U,$J,358.4,1578,0)
 ;;=MISCELLANEOUS/SYMPTOMS^10^171
 ;;^UTILITY(U,$J,358.4,1579,0)
 ;;=MISC/CONDITIONS/STATES^9^171
 ;;^UTILITY(U,$J,358.4,1580,0)
 ;;=INFECTIONS-VENEREAL^7^171
 ;;^UTILITY(U,$J,358.4,1581,0)
 ;;=INFECTIONS-RENAL/URETER^6^171
 ;;^UTILITY(U,$J,358.4,1582,0)
 ;;=INFECTIONS-PROSTATE^5^171
 ;;^UTILITY(U,$J,358.4,1583,0)
 ;;=INFECTIONS-KIDNEY^4^171
 ;;^UTILITY(U,$J,358.4,1584,0)
 ;;=INFECTION-MISCELLANEOUS^3^171
 ;;^UTILITY(U,$J,358.4,1585,0)
 ;;=NEOPLASIA-BLADDER/URETHRA^11^171
 ;;^UTILITY(U,$J,358.4,1586,0)
 ;;=NEOPLASIA-PROSTATE^14^171
 ;;^UTILITY(U,$J,358.4,1587,0)
 ;;=NEOPLASIA-KIDNEY/URETER^13^171
 ;;^UTILITY(U,$J,358.4,1588,0)
 ;;=NEOPLASIA-EXTERNAL GENITALIA^12^171
 ;;^UTILITY(U,$J,358.4,1589,0)
 ;;=COMPLICATIONS^2^171
 ;;^UTILITY(U,$J,358.4,1590,0)
 ;;=NEW PATIENT^2^172
 ;;^UTILITY(U,$J,358.4,1591,0)
 ;;=ESTABLISHED PATIENT^1^172
 ;;^UTILITY(U,$J,358.4,1592,0)
 ;;=CONSULTATIONS^3^172
 ;;^UTILITY(U,$J,358.4,1593,0)
 ;;=RESPIRATORY^8^173
 ;;^UTILITY(U,$J,358.4,1594,0)
 ;;=CARDIOVASCULAR^4^173
 ;;^UTILITY(U,$J,358.4,1595,0)
 ;;=ABDOMINAL PAIN^2^173
 ;;^UTILITY(U,$J,358.4,1596,0)
 ;;=AFTERCARE POST SURGERY^3^173
 ;;^UTILITY(U,$J,358.4,1597,0)
 ;;=COMMON VASCULAR DX^1^173
 ;;^UTILITY(U,$J,358.4,1598,0)
 ;;=POST-OP COMPLICATIONS^7^173
 ;;^UTILITY(U,$J,358.4,1599,0)
 ;;=METASTATIC CANCER SITES^6^173
 ;;^UTILITY(U,$J,358.4,1600,0)
 ;;=GENERAL/SIGNS & SYMPTOMS^5^173
 ;;^UTILITY(U,$J,358.4,1601,0)
 ;;=DEBRIDEMENT^2^174
 ;;^UTILITY(U,$J,358.4,1602,0)
 ;;=I&D/ASPIRATION^3^174
 ;;^UTILITY(U,$J,358.4,1603,0)
 ;;=UNNA BOOT^4^174
 ;;^UTILITY(U,$J,358.4,1604,0)
 ;;=PEG TUBE^5^174
 ;;^UTILITY(U,$J,358.4,1605,0)
 ;;=WOUND VAC DRESSING^6^174
 ;;^UTILITY(U,$J,358.4,1606,0)
 ;;=VASCULAR PROCEDURES^1^174
